Oramed Pharmaceuticals (ORMP) versus Idera Pharmaceuticals (IDRA) Head to Head Review

Oramed Pharmaceuticals (NASDAQ: ORMP) and Idera Pharmaceuticals (NASDAQ:IDRA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, risk, dividends, institutional ownership and profitability.

Institutional and Insider Ownership

2.1% of Oramed Pharmaceuticals shares are owned by institutional investors. Comparatively, 27.0% of Idera Pharmaceuticals shares are owned by institutional investors. 27.5% of Oramed Pharmaceuticals shares are owned by insiders. Comparatively, 12.4% of Idera Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Oramed Pharmaceuticals has a beta of 0.22, suggesting that its share price is 78% less volatile than the S&P 500. Comparatively, Idera Pharmaceuticals has a beta of 2.2, suggesting that its share price is 120% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings for Oramed Pharmaceuticals and Idera Pharmaceuticals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oramed Pharmaceuticals 0 0 2 0 3.00
Idera Pharmaceuticals 0 0 5 0 3.00

Oramed Pharmaceuticals presently has a consensus price target of $22.50, suggesting a potential upside of 204.88%. Idera Pharmaceuticals has a consensus price target of $5.40, suggesting a potential upside of 184.21%. Given Oramed Pharmaceuticals’ higher probable upside, analysts clearly believe Oramed Pharmaceuticals is more favorable than Idera Pharmaceuticals.

Profitability

This table compares Oramed Pharmaceuticals and Idera Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Oramed Pharmaceuticals -169.17% -49.94% -25.64%
Idera Pharmaceuticals -313.78% -60.80% -55.07%

Valuation & Earnings

This table compares Oramed Pharmaceuticals and Idera Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Oramed Pharmaceuticals $2.46 million 43.11 -$10.48 million ($0.77) -9.58
Idera Pharmaceuticals $16.20 million 22.94 -$38.38 million ($0.34) -5.59

Oramed Pharmaceuticals has higher earnings, but lower revenue than Idera Pharmaceuticals. Oramed Pharmaceuticals is trading at a lower price-to-earnings ratio than Idera Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Oramed Pharmaceuticals beats Idera Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc. (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection. Oramed’s delivery platform protects protein sand enhances their absorption, allowing them to reach the blood stream through the portal vein. The Company’s products include ORMD-0801, Oral insulin capsule; ORMD 0901, Oral Exenatide capsule; and combination therapy of ORMD 0801 + ORMD 0901. ORMD-0801 is under phase II A clinical trials. ORMD-0901 is under preclinical/Investigational New Drug (IND) stage under phase I B.

Idera Pharmaceuticals Company Profile

Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting technology and third-generation antisense (3GA) technology. Using TLR technology, the Company designs synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. Using its 3GA technology, the Company is developing drug candidates to turn off the messenger ribo nucleic acid (mRNA) associated with disease causing genes. The Company’s drug candidates include IMO-8400, IMO-2125 and IMO-9200. The Company has designed TLR antagonists and agonists to act by modulating the activity of targeted TLRs. It is developing its 3GA technology to turn off the mRNA associated with disease causing genes.

Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply